| Oct 28 |
Moderna’s Stock-Price Target Slashed. It’s About Vaccines.
|
| Oct 28 |
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
|
| Oct 26 |
Who Should Get Covid and Flu Vaccines This Year—and the Best Time to Get Them
|
| Oct 25 |
Moderna snaps six days of losses, trades in green
|
| Oct 24 |
Moderna Named a Top Employer by Science for Tenth Consecutive Year
|
| Oct 24 |
Moderna’s norovirus vaccine enters Phase III trials in the UK
|
| Oct 23 |
Moderna, Inc. (NASDAQ:MRNA) Isn’t Seeing Any Love From Mutual Or Hedge Funds
|
| Oct 23 |
PFE Gets FDA Nod for Expanded Use of RSV Vaccine Abrysvo
|
| Oct 23 |
Moderna, Inc. (MRNA): Leading the Way in mRNA Vaccines and Respiratory Health
|
| Oct 23 |
Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence
|
